Influence of concomitant antiepileptic drugs on plasma lamotrigine concentration in adult Japanese epilepsy patients

Biological and Pharmaceutical Bulletin

Volumn 35, Issue 4, 2012, Pages 487-493

  Yamamoto, Yoshiaki ^a,b   Inoue, Yushi ^a   Matsuda, Kazumi ^a   Takahashi, Yukitoshi ^a   Kagawa, Yoshiyuki ^b  

^a SHIZUOKA INSTITUTE OF EPILEPSY AND NEUROLOGICAL DISORDERS   (Japan)

^b UNIVERSITY OF SHIZUOKA   (Japan)

Author keywords

Concentration dose ratio; Drug interaction; Lamotrigine; Therapeutic drug monitoring

Indexed keywords

ANTICONVULSIVE AGENT; CARBAMAZEPINE; CLOBAZAM; CLONAZEPAM; ENZYME INDUCING AGENT; ETHOSUXIMIDE; ETIRACETAM; GABAPENTIN; LAMOTRIGINE; PHENOBARBITAL; PHENYTOIN; TOPIRAMATE; VALPROIC ACID; ZONISAMIDE;

ADOLESCENT; ADULT; AGED; ARTICLE; COMBINATION CHEMOTHERAPY; CONCENTRATION RESPONSE; CONCENTRATION TO DOSE RATIO; CONTROLLED STUDY; DOSE CALCULATION; DRUG BLOOD LEVEL; DRUG INHIBITION; DRUG MEGADOSE; DRUG METABOLISM; EPILEPSY; FEMALE; HUMAN; JAPANESE; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; RETROSPECTIVE STUDY;

ADOLESCENT; ADULT; AGED; ANTICONVULSANTS; ASIAN CONTINENTAL ANCESTRY GROUP; DRUG COMBINATIONS; EPILEPSY; FEMALE; HUMANS; MALE; MIDDLE AGED; TRIAZINES; YOUNG ADULT;

EID: 84859446814     PISSN: 09186158     EISSN: 13475215     Source Type: Journal    
DOI: 10.1248/bpb.35.487     Document Type: Article

References (28)

1. Kilpatrick ES, Forrest G, Brodie MJ. Concentration-effect and concentration- toxicity relations with lamotrigine: a prospective study. Epilepsia, 37, 534-538 (1996).
2. Bartoli A, Guerrini R, Belmonte A, Alessandrì MG, Gatti G, Perucca E. The influence of dosage, age, and comedication on steady state plasma lamotrigine concentrations in epileptic children: a prospective study with preliminary assessment of correlations with clinical response. Ther. Drug Monit., 19, 252-260 (1997).
3. Chong E, Dupuis LL. Therapeutic drug monitoring of lamotrigine. Ann. Pharmacother., 36, 917-920 (2002).
4. Johannessen SI, Tomson T. Pharmacokinetic variability of newer antiepileptic drugs: when is monitoring needed? Clin. Pharmacokinet., 45, 1061-1075 (2006).
5. Hirsch LJ, Weintraub D, Du Y, Buchsbaum R, Spencer HT, Hager M, Straka T, Bazil CW, Adams DJ, Resor SR Jr, Morrell MJ. Correlating lamotrigine serum concentrations with tolerability in patients with epilepsy. Neurology, 63, 1022-1026 (2004).
6. Morris RG, Black AB, Harris AL, Batty AB, Sallustio BC. Lamotrigine and therapeutic drug monitoring: retrospective survey following the introduction of a routine service. Br. J. Clin. Pharmacol., 46, 547-551 (1998).
7. Magdalou J, Herber R, Bidault R, Siest G. In vitro N-glucuronidation of a novel antiepileptic drug, lamotrigine, by human liver microsomes. J. Pharmacol. Exp. Ther., 260, 1166-1173 (1992).
8. Rowland A, Elliot DJ, Williams JA, Mackenzie PI, Dickinson RG, Miners JO. In vitro characterization of lamotrigine N2-glucuronidation and the lamotrigine-valproic acid interaction. Drug Metab. Dispos., 34, 1055-1062 (2006).
9. Posner J, Cohen AF, Land G, Winton C, Peck AW. The pharmacokinetics of lamotrigine (BW430C) in healthy subjects with unconjugated hyperbilirubinaemia (Gilbert's syndrome). Br. J. Clin. Pharmacol., 28, 117-120 (1989).
10. May TW, Rambeck B, Jürgens U. Serum concentrations of lamotrigine in epileptic patients: the influence of dose and comedication. Ther. Drug Monit., 18, 523-531 (1996).
11. Grasela TH, Fiedler-Kelly J, Cox E, Womble GP, Risner ME, Chen C. Population pharmacokinetics of lamotrigine adjunctive therapy in adults with epilepsy. J. Clin. Pharmacol., 39, 373-384 (1999).
12. Armijo JA, Bravo J, Cuadrado A, Herranz JL. Lamotrigine serum concentration-to-dose ratio: influence of age and concomitant antiepileptic drugs and dosage implications. Ther. Drug Monit., 21, 182-190 (1999).
13. Gidal BE, Anderson GD, Rutecki PR, Shaw R, Lanning A. Lack of an effect of valproate concentration on lamotrigine pharmacokinetics in developmentally disabled patients with epilepsy. Epilepsy Res., 42, 23-31 (2000).
14. Rivas N, Buelga DS, Elger CE, Santos-Borbujo J, Otero MJ, Domínguez-Gil A, García MJ. Population pharmacokinetics of lamotrigine with data from therapeutic drug monitoring in German and Spanish patients with epilepsy. Ther. Drug Monit., 30, 483-489 (2008).
15. Lalic M, Cvejic J, Popovic J, Bozic K, Golocorbin-Kon S, Al-Salami H, Mikov M. Lamotrigine and valproate pharmacokinetics interactions in epileptic patients. Eur. J. Drug Metab. Pharmacokinet., 34, 93-99 (2009).
16. Battino D, Croci D, Granata T, Estienne M, Pisani F, Avanzini G. Lamotrigine plasma concentrations in children and adults: influence of age and associated therapy. Ther. Drug Monit., 19, 620-627 (1997).
17. Hussein Z, Posner J. Population pharmacokinetics of lamotrigine monotherapy in patients with epilepsy: retrospective analysis of routine monitoring data. Br. J. Clin. Pharmacol., 43, 457-465 (1997).
18. Gulcebi MI, Ozkaynakci A, Goren MZ, Aker RG, Ozkara C, Onat FY. The relationship between UGT1A4 polymorphism and serum concentration of lamotrigine in patients with epilepsy. Epilepsy Res., 95, 1-8 (2011).
19. Blanca Sánchez M, Herranz JL, Leno C, Arteaga R, Oterino A, Valdizán EM, Nicolas JM, Adín J, Shushtarian M, Armijo JA. UGT2B7--161C>T polymorphism is associated with lamotrigine concentration-to-dose ratio in a multivariate study. Ther. Drug Monit., 32, 177-184 (2010).
20. Ehmer U, Vogel A, Schütte JK, Krone B, Manns MP, Strassburg CP. Variation of hepatic glucuronidation: Novel functional polymorphisms of the UDP-glucuronosyltransferase UGT1A4. Hepatology, 39, 970-977 (2004).
21. Saeki M, Saito Y, Jinno H, Sai K, Hachisuka A, Kaniwa N, Ozawa S, Kawamoto M, Kamatani N, Shirao K, Minami H, Ohtsu A, Yoshida T, Saijo N, Komamura K, Kotake T, Morishita H, Kamakura S, Kitakaze M, Tomoike H, Sawada J. Genetic variations and haplotypes of UGT1A4 in a Japanese population. Drug Metab. Pharmacokinet., 20, 144-151 (2005).
22. Saeki M, Saito Y, Jinno H, Tanaka-Kagawa T, Ohno A, Ozawa S, Ueno K, Kamakura S, Kamatani N, Komamura K, Kitakaze M, Sawada J. Single nucleotide polymorphisms and haplotype frequencies of UGT2B4 and UGT2B7 in a Japanese population. Drug Metab. Dispos., 32, 1048-1054 (2004).
23. Saito K, Moriya H, Sawaguchi T, Hayakawa T, Nakahara S, Goto A, Arimura Y, Imai K, Kurosawa N, Owada E, Miyamoto A. Haplotype analysis of UDP-glucuronocyltransferase 2B7 gene (UGT2B7) polymorphisms in healthy Japanese subjects. Clin. Biochem., 39, 303-308 (2006).
24. Bhasker CR, McKinnon W, Stone A, Lo AC, Kubota T, Ishizaki T, Miners JO. Genetic polymorphism of UDP-glucuronosyltransferase 2B7 (UGT2B7) at amino acid 268: ethnic diversity of alleles and potential clinical significance. Pharmacogenetics, 10, 679-685 (2000).
25. Lampe JW, Bigler J, Bush AC, Potter JD. Prevalence of polymorphisms in the human UDP-glucuronosyltransferase 2B family: UGT2B4(D458E), UGT2B7(H268Y), and UGT2B15(D85Y). Cancer Epidemiol. Biomarkers Prev., 9, 329-333 (2000).
26. Chung JY, Cho JY, Yu KS, Kim JR, Lim KS, Sohn DR, Shin SG, Jang IJ. Pharmacokinetic and pharmacodynamic interaction of lorazepam and valproic acid in relation to UGT2B7 genetic polymorphism in healthy subjects. Clin. Pharmacol. Ther., 83, 595-600 (2008).
27. Gidal BE, Sheth R, Parnell J, Maloney K, Sale M. Evaluation of VPA dose and concentration effects on lamotrigine pharmacokinetics: implications for conversion to lamotrigine monotherapy. Epilepsy Res., 57, 85-93 (2003).
28. Blanco-Serrano B, Otero MJ, Santos-Buelga D, García-Sánchez MJ, Serrano J, Domínguez-Gil A. Population estimation of valproic acid clearance in adult patients using routine clinical pharmacokinetic data. Biopharm. Drug Dispos., 20, 233-240 (1999).